 |
 |
 |
 |
|
|
The Team Genomic Health's management team has extensive experience in the biotechnology and genomic industries. Members of the management team have demonstrated success in starting genomic businesses, developing leading drugs, launching new products, and building successful organizations. Genomic Health Management Team (click on the names to learn more) 
Genomic Health Board Members (click on the names to learn more)
Randy Scott, Ph.D. has served as Chairman of the Board and Chief Executive Officer since Genomic Health’s inception in August 2000. Randy was a founder of Incyte Corporation, a genomic information company, and served Incyte in various roles, including Chairman of the Board from August 2000 to December 2001, President from January 1997 to August 2000, and Chief Scientific Officer from March 1995 to August 2000. Randy holds a B.S. in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas. Kim Popovits has served as President and Chief Operating Officer since February 2002, and as a director since March 2002. From November 1987 to February 2002, Kim served in various roles at Genentech, Inc., a biotechnology company, most recently as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech in November 1987, she served as Division Manager for American Critical Care, a Division of American Hospital Supply. Kim holds a B.A. in Business from Michigan State University. Joffre Baker, Ph.D. has served as Chief Scientific Officer since December 2000. From March 1997 to October 2000, Joffre served as Vice President for Research Discovery at Genentech, Inc. From March 1993 to October 2000, Joffre oversaw Research Discovery at Genentech, which included the Departments of Cardiovascular Research, Oncology, Immunology, Endocrinology, and Pathology. From July 1991 to October 1993, he served as Genentech’s Director of Cardiovascular Research. Prior to joining Genentech, Joffre was a faculty member in the Department of Biochemistry at the University of Kansas. He holds a B.S. in Biology and Chemistry from the University of California, San Diego and a Ph.D. in Biochemistry from the University of Hawaii. Steve Shak, M.D. has served as Chief Medical Officer since December 2000. From July 1996 to October 2000, Steve served in various roles in Medical Affairs at Genentech, Inc., most recently as Senior Director and Staff Clinical Scientist. From November 1989 to July 1996, Steve served as a Director of Discovery Research at Genentech, where he was responsible for Pulmonary Research, Immunology, and Pathology. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for metastatic breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, anti-VEGF (Avastin™). In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease, Cystic Fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a B.A. in Chemistry from Amherst College and an M.D. from New York University School of Medicine, and completed his post-doctoral training at University of California, San Francisco. Brad Cole has served as Executive Vice President, Operations and Chief Financial Officer since January 2008; as Executive Vice President and Chief Financial Officer from July 2004 until December 2007; and has served as Secretary from February 2005. From December 1997 to May 2004, he served in various positions at Guidant Corporation, a medical device company, most recently as Vice President, Finance and Business Development for the Endovascular Solutions Group from January 2001 until May 2004, as Vice President and General Manager of the Vascular Surgery Business Unit from December 1998 until December 2000 and as Vice President, Finance and IT Systems of the Cardiac and Vascular Surgery Group from December 1997 until November 1998. From July 1994 to December 1997, Brad was Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a medical device company acquired by Guidant Corporation. From December 1988 to February 1994, he served as Vice President, Finance and Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company. Brad holds a B.S. in Business from Biola University and an M.B.A. from San Jose State University. David Logan has served as Senior Vice President, Commercial since December of 2007 and as Vice President of Sales (Managed Care, Operations and Sales) since 2003. Prior to Genomic Health, Inc., David served in various roles at Genentech, Inc., most recently as Vice President of Specialty Therapeutics (Sales and Marketing) in 2002 and prior to that he held Senior Director, Director and Management positions in Marketing/Sales, Managed Care, and Sales Operations from 1987 to 2002. Prior to joining Genentech, David held positions in sales and sales management at Pfizer Inc. after spending four years in the United States Army. David holds a bachelor’s degree in communications from the University of Alabama. Tricia Tomlinson has served as Senior Vice President, Human Resources since November 2007. Prior to joining Genomic Health, Inc, Tricia served as Vice President of Human Resources at Azul Systems, a leader in enterprise server appliances, where she held worldwide responsibility for all human resources functions and activities. Before joining Azul, Tricia served as Vice President Human Resources at palmOne. Prior to palmOne Tricia was Vice President Human Resources for Handspring, Inc. Tricia also served as a senior ranking officer of the Edify Corporation where she managed all aspects of the worldwide human resources function. She also held executive human resources management positions at Xerox Corporation and Synopsys and in the early 80's to early 90's Tricia worked at Apple Computer where she helped pioneer cutting edge human resources programs. She holds a Bachelor of Arts in Sociology from Pomona College and is a graduate of the Program for Management Development at Harvard Business School. Julian Baker has served as a director of Genomic Health since January 2001. Mr. Baker is a Managing Member of Baker Bros. Advisors, LLC which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker’s firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family, now known as Baker/Tisch investments. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. He is also a director of Incyte Corporation, Neurogen Corporation, Theravance, Inc. and Trimeris, Inc. Mr. Baker holds an A.B. in Social Studies from Harvard University. Brook Byers has served as a director of Genomic Health since January 2001. Mr. Byers is a general partner of Kleiner Perkins Caufield & Byers, a venture capital firm which he joined in 1977. He was the founding president and chairman of four life-sciences companies: Hybritech Inc., IDEC Pharmaceuticals Corporation, InSite Vision Inc. and Ligand Pharmaceuticals Inc. Mr. Byers currently serves as a director of Five Prime Therapeutics, XDx, Cardio DX, OptiMedica and a number of privately held technology, healthcare and biotechnology companies. Mr. Byers holds a B.S. in electrical engineering from the Georgia Institute of Technology and an M.B.A. from the Stanford Graduate School of Business. Fred Cohen, M.D., Ph.D. has served as a director of Genomic Health since April 2002. In 2001, Dr. Cohen joined TPG Ventures, a venture capital firm, as a Managing Director. Dr. Cohen is also a Professor of Medicine and Pharmacology at the University of California, San Francisco, where he has taught since July 1988. Dr. Cohen is a director of Matrix Laboratories Ltd. and a number of privately held companies. Dr. Cohen holds a B.S. from Yale University, a Ph.D from Oxford University, and an M.D. from Stanford University. Samuel Colella has served as a director of Genomic Health since January 2001. In 1999, Mr. Colella co-founded Versant Ventures, a healthcare and biotechnology venture capital firm. From 1984 to 1999, Mr. Colella was a general partner of Institutional Venture Partners, a venture capital firm. Mr. Colella currently serves as a director of Symyx Technologies, Inc. and a number of privately held technology and biotechnology companies. Mr. Colella has a B.S. in Business and Engineering from the University of Pittsburgh and an M.B.A. from the Stanford Graduate School of Business. Randall Livingston has served as a director of Genomic Health since October 2004. In 2001, Mr. Livingston was appointed Vice President for Business Affairs and Chief Financial Officer of Stanford University. From 1999 to 2001, Mr. Livingston served as Executive Vice President and Chief Financial Officer of OpenTV Corp., a provider of interactive television services. From 1996 until 1999, Mr. Livingston served as a consultant and part-time executive for several Silicon Valley technology companies. Prior to 1996, Mr. Livingston worked for Heartport, Inc., Taligent, Apple Computer, Ingres Corporation and McKinsey & Company. Mr. Livingston holds a B.S. in Mechanical Engineering from Stanford University and an M.B.A. from the Stanford Graduate School of Business. Woodrow Myers, M.D., M.B.A. has served director of Genomic Health since April 2006. Dr. Myers is a managing Director at Myers Ventures LLC. Dr. Myers is a director at Stanford University Hospital and visiting adjunct professor of medicine at the UCLA School of Medicine. Dr. Myers has served as the former executive vice president and chief medical officer of WellPoint, Inc., where he established the Health Quality Assurance Division. Prior to his position at WellPoint, Dr. Myers served as the director of health care management at the Ford Motor Company where he initiated quality assurance metrics for Ford healthcare vendors and established new global health and safety policies to benefit Ford and its employees. He is a former health commissioner for the city of New York and the state of Indiana, past chairman of the Visiting Committee for the Harvard School of Public Health and has served as a member of the Harvard University Board of Overseers and the Stanford University Board of Trustees. Dr. Myers holds medical and business degrees from Harvard and Stanford, respectively. |
 |
|
|
 |
|
| Copyright © 2008 Genomic Health, Inc. All rights reserved. | | Contact Us | Site Map | Privacy | Terms and Conditions | |